CancerDrs

Pancreatic Cancer clinical trials in Illinois

39 actively recruiting pancreatic cancer trials at 69 sites across Illinois.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …

Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in Illinois:
  • Rush-Copley Medical Center — Aurora, Illinois
  • Advocate Outpatient Center - Aurora — Aurora, Illinois
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
  • Illinois CancerCare-Canton — Canton, Illinois
  • Illinois CancerCare-Carthage — Carthage, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Sites in Illinois:
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
  • Illinois CancerCare-Canton — Canton, Illinois
  • Memorial Hospital of Carbondale — Carbondale, Illinois
  • SIH Cancer Institute — Carterville, Illinois
  • Illinois CancerCare-Carthage — Carthage, Illinois
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…

Sponsor: Pfizer
NCT ID: NCT06989437
Sites in Illinois:
  • Cancer Care Specialists of Illinois — Decatur, Illinois
  • Decatur Memorial Hospital — Decatur, Illinois
  • Hope and Healing Clinical Research LLC — Hinsdale, Illinois
  • Hope and Healing Clinical Research LLC New Lenox- Research Department — New Lenox, Illinois
  • Cancer Care Specialists of Illinois - Cancer Care Center of O'Fallon — O'Fallon, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in Illinois:
  • Investigative Site US079 — Chicago, Illinois
  • Investigative Site US030 — Evanston, Illinois
  • Investigative Site US005 — Naperville, Illinois
  • Investigative Site US009 — Springfield, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…

Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Illinois:
  • Ann & Robert H. Lurie Children's Hospital of Chicago (Adults and Pediatrics) — Chicago, Illinois
  • University of Chicago Medical Center - Duchossois Center for Advanced Medicine (Adults only) — Chicago, Illinois
  • Loyola University Medical Center (Adults and Pediatrics) — Maywood, Illinois
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Sponsor: Immuneering Corporation
NCT ID: NCT07562152
Sites in Illinois:
  • Illinois Cancer Specialists — Arlington Heights, Illinois
  • City of Hope — Chicago, Illinois
  • OSF Medical Center — Peoria, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in Illinois:
  • OSF Saint Anthony's Health Center — Alton, Illinois
  • Rush-Copley Medical Center — Aurora, Illinois
  • Illinois CancerCare-Bloomington — Bloomington, Illinois
  • Illinois CancerCare-Canton — Canton, Illinois
  • Memorial Hospital of Carbondale — Carbondale, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Illinois:
  • OSF Saint Anthony's Health Center — Alton, Illinois
  • Rush-Copley Medical Center — Aurora, Illinois
  • Saint Mary's Hospital — Centralia, Illinois
  • Northwestern University — Chicago, Illinois
  • University of Illinois — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…

Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in Illinois:
  • Ohio State University-Telemedicine — Champaign, Illinois
  • Ohio State University-Telemedicine — Chicago, Illinois
  • Ohio State University Telemedicine — Quincy, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nod…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04172532
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…

Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Illinois:
  • Hope and Healing Cancer Services — Hinsdale, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in partici…

Sponsor: Genentech, Inc.
NCT ID: NCT05968326
Sites in Illinois:
  • Northwestern Memorial Hospital — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Illinois:
  • Lurie Children's Hospital-Chicago — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab…

Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06922591
Sites in Illinois:
  • Northwestern Memorial Hospital — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Illinois:
  • Orchard Healthcare Research Inc. — Skokie, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specif…

Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT05732831
Sites in Illinois:
  • University Chicago Medicine — Chicago, Illinois
  • Carle Cancer Center — Urbana, Illinois
  • Midwestern Regional Medical Center, City of Hope Chicago — Zion, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04924075
Sites in Illinois:
  • Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130) — Chicago, Illinois
  • Northwestern Medicine Cancer Center - Warrenville ( Site 0134) — Warrenville, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…

Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in Illinois:
  • Research Site — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source

Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.

Sponsor: CivaTech Oncology
NCT ID: NCT02843945
Sites in Illinois:
  • Rush University Cancer Center — Chicago, Illinois
  • Advocate Christ Medical Center — Oak Lawn, Illinois
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started to nearby …

Sponsor: Northwestern University
NCT ID: NCT05733000
Sites in Illinois:
  • Northwestern University — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Illinois:
  • Ingalls Family Care Center — Calumet City, Illinois
  • UChicago Medicine - River East — Chicago, Illinois
  • The University Of Chicago — Chicago, Illinois
  • University of Chicago Medical Center — Chicago, Illinois
  • UChicago Medicine at Ingalls - Flossmoor — Flossmoor, Illinois
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Sponsor: Bristol-Myers Squibb
NCT ID: NCT05245500
Sites in Illinois:
  • Local Institution - 124 — Chicago, Illinois
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Ce…

Sponsor: AbbVie
NCT ID: NCT05005403
Sites in Illinois:
  • University of Illinois Hospital and Health Sciences System /ID# 251750 — Chicago, Illinois
  • University of Chicago Medical Center /ID# 276271 — Chicago, Illinois
View on ClinicalTrials.gov →

Showing 25 of 39 trials with sites in Illinois. See all pancreatic cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07